Brokerages Set $172.00 Price Target for Tilray Inc (TLRY)
Shares of Tilray Inc (NASDAQ:TLRY) have been assigned a consensus broker rating score of 2.33 (Buy) from the three brokers that cover the stock, Zacks Investment Research reports. Two equities research analysts have rated the stock with a hold recommendation and one has issued a strong buy recommendation on the company.
Brokers have set a one year consensus price target of $172.00 for the company and are forecasting that the company will post ($0.14) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Tilray an industry rank of 87 out of 255 based on the ratings given to its competitors.
TLRY has been the subject of several research reports. Cowen boosted their price objective on shares of Tilray from $62.00 to $172.00 and gave the company an “outperform” rating in a research report on Tuesday. Roth Capital initiated coverage on shares of Tilray in a research report on Tuesday, August 14th. They issued a “buy” rating and a $35.00 price objective for the company. Finally, Northland Securities cut shares of Tilray from an “outperform” rating to a “market perform” rating in a research report on Thursday, September 6th.
A hedge fund recently bought a new stake in Tilray stock. Bank of Montreal Can purchased a new position in Tilray Inc (NASDAQ:TLRY) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 17,179 shares of the company’s stock, valued at approximately $2,467,000.
Tilray stock traded up $16.35 during trading hours on Friday, hitting $148.30. The company had a trading volume of 4,233,724 shares, compared to its average volume of 8,587,406. Tilray has a 1 year low of $20.10 and a 1 year high of $300.00.
Tilray (NASDAQ:TLRY) last released its quarterly earnings data on Tuesday, August 28th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.08). The business had revenue of $9.70 million for the quarter, compared to the consensus estimate of $9.01 million. Tilray’s revenue was up 94.0% compared to the same quarter last year. As a group, research analysts expect that Tilray will post -0.45 earnings per share for the current fiscal year.
Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc was incorporated in 2018 and is headquartered in Nanaimo, Canada.
Featured Story: How Do You Calculate Return on Equity (ROE)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tilray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tilray and related companies with MarketBeat.com's FREE daily email newsletter.